08.06.2021 | Forbes
By Steve Brozak
In the last 24-hours vaccine makers, Moderna and Novavax both released positive, but limited information emphasizing the strengths of their respective vaccines over separate 6-month periods. Additionally, Novavax issued some not so positive news that there were some FDA manufacturing issues the US Government had asked the company to resolve, and I am quite certain that these are solvable hurdles. What was of greater interest was information released by both companies on their individual progress with booster candidates, and therein the real Covid-19 discussion must begin.
As a forward, vaccines are still the most effective FDA authorized defense we now have against the SARS-CoV-2 virus that causes Covid-19 infections, but that defense weakens over time. One measure of vaccine strength is the level of neutralizing antibodies. But there is a difference in antibody protection between those who were vaccinated and those who have recovered from a Covid-19 infection. Antibody counts in those who have received a vaccine decline more than patients recovering from acute infections.
To read the entire article on Forbes, please click here…
